Trial Profile

ELEVATE: Temozolomide + nivolumab in MGMT-deficient oesophagogastric cancer

Status: Not yet recruiting

Phase of Trial: Phase II

Latest Information Update: 03 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nivolumab (Primary) ; Temozolomide (Primary)
Indications Gastric cancer; Oesophageal cancer
Focus Therapeutic Use
Acronyms ELEVATE

Most Recent Events

08 Mar 2023 Planned End Date changed from 31 Dec 2024 to 30 Mar 2025.
01 Sep 2022 Trial design published in the BMC Cancer.
04 Aug 2021 Status changed from recruiting to not yet recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com